NCT07218809View on ClinicalTrials.gov

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,100

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

November 17, 2028

Study Completion Date

May 27, 2030

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG

AZD5335

antibody drug conjugate

DRUG

Mirvetuximab Soravtansine (MIRV)

antibody drug conjugate

DRUG

Paclitaxel

chemotherapy

DRUG

Pegylated liposomal Doxorubicin (PLD)

chemotherapy

DRUG

Topotecan

chemotherapy

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

European Network of Gynecological Oncological Trial Groups (ENGOT)

UNKNOWN

collaborator

GOG Foundation, Inc. (GOG Foundation)

UNKNOWN

collaborator

Ventana Medical Systems, Inc

UNKNOWN

lead

AstraZeneca

INDUSTRY